Category Specific RSS

Categories: News

New Anatara trial to tackle anxiety, stress and depression with diet supplement

Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression.

3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment of irritable bowel syndrome. 3FDC is designed to exert its effects on the microbiome of the large intestine. The gut-brain axis is a complex communication system in our bodies. The quality of the gut microbiome is proven to have effects on the emotional and cognitive centres of the brain. The interaction between the gut and brain is a hot topic in scientific research, evidenced by the proliferation of experimental studies in recent years that have revolutionised medicine’s understanding of the links between these two systems. 

The randomised, double-blinded, placebo-controlled study will take place at CSIRO’s Nutrition and Health Research clinic in Adelaide. 100 participants will be dosed with placebo or 3FDC for 6 weeks. Anatara’s primary outcome is to see a clinically significant reduction in Hospital Anxiety and Depression Scale (HADS) scores. They will also utilise mood and well-being questionnaires, gut symptom ratings and blood plasma markers. 

Recruitment of participants and development of guidelines has commenced. Anatara hopes to dose the first participants in Q3 2021. 

Anatara has already had success with proof of concept studies for their treatments and has gained approval by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for use of a natural, non antibiotic product to treat diarrhoea in livestock. 

Company CEO Steve Lydeamore emphasised the “major unmet need and significant market opportunity for an evidence- based complementary medicine for stress, anxiety and depression”. The study puts Anatara one step closer to filling the market gap. 

According to Beyond Blue, 1 in 4 Australians will experience an anxiety condition in their lifetime.

Samantha Freidin

Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Recent Posts

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

4 days ago

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

2 weeks ago

Stakk Secures T-Mobile Contract to Power Super App Expansion

Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…

3 weeks ago

Medibank Backs Emyria with Landmark Depression Care Deal

Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…

4 weeks ago

NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI

NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…

1 month ago

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…

2 months ago